Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors

NCT ID: NCT00933296

Last Updated: 2017-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-07-31

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component. Other frequent signs include joint, bone and muscle pain, enlarged spleen, liver and lymph nodes, increased blood sedimentation rate (BSR), elevated neutrophil count and abnormalities on bone morphologic investigations. In 2001, the investigators proposed criteria to diagnose this syndrome, which are currently admitted in the literature. The main complications of the Schnitzler syndrome are a difficult-to-control inflammatory anemia, AA-amyloidosis and malignant B lymphoproliferative disorders. About 15% of patients with a Schnitzler will eventually develop a lymphoproliferative disorder; thus this syndrome allows studying the relationship between lymphomagenesis and inflammation. By many aspects, the Schnitzler syndrome is reminiscent of auto-inflammatory syndromes. Though the term auto-inflammatory disease is as to yet restricted to diseases with Mendelian inheritance, some polygenic inflammatory diseases like for example Crohn's disease clearly involve pathogenetic pathways shared with the monogenic auto-inflammatory syndromes. The investigators stipulate that this could also be the case in the Schnitzler syndrome for the following reasons: (1) this is a recurrent fever of unknown cause; (2) the peculiar eruption, characterized pathologically by a neutrophilic infiltrate very similar to the one observed in the auto-inflammatory cryopyrinopathies (CINCA/NOMID syndrome, Muckle-Wells syndrome and familial cold-urticaria); the investigators recently individualized this particular eruption, significantly associated with systemic inflammatory disease, within the group of neutrophilic urticarias (Kieffer et al. Medicine, in press); (3) the occurrence of aseptic neutrophilic osteitis, very similar to the one reported in patients with Majeed syndrome, another auto-inflammatory syndrome; (4) a significant increase of neutrophil count, not otherwise explained; (5) a spectacular response to the IL-1 inhibitor, within hours after the first injection, similar to what is reported in the PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome or the cryopyrinopathies, suggesting a direct pathogenic effect of IL-1.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schnitzler Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A Patients with the Schnitzler syndrome

Patients with the Schnitzler syndrome

No interventions assigned to this group

B Control subjects:

B1 healthy B2 other diseases

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with the Schnitzler syndrome according to criteria established by Lipsker D et al. Medicine (Baltimore) 2001;80:37-44

Exclusion Criteria

* children and pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dan Lipsker, Pr

Role: PRINCIPAL_INVESTIGATOR

HUS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Besançon Service de Dermatologie

Besançon, , France

Site Status

Service de DermatologieCHU Morvan5 avenue Foch

Brest, , France

Site Status

Centre Hospitalier Général Bd Yves du Manoir

Dax, , France

Site Status

Service de Rhumatologie Centre Hospitalier du Mans

Le Mans, , France

Site Status

Service de Médecine Interne Hôpital Claude-Huriez

Lille, , France

Site Status

Service de DermatologieHôtel Dieu

Lyon, , France

Site Status

Service médecine interne et thérapeutique Hôpital sainte marguerite

Marseille, , France

Site Status

Service de Dermatologie Hôpital Saint Eloi 80 avenue A Fliche

Montpellier, , France

Site Status

Service de dermatologie CHU Hôtel Dieu1 place Alexis Ricordeau

Nantes, , France

Site Status

Unité de médecine interne Centre Hospitalier G. Renon

Niort, , France

Site Status

Service d'immuno-hématologie Hôpital St-Louis 1 av Claude Vellefaux

Paris, , France

Site Status

Service de médecine interne Hôpital Tenon4, rue de la Chine

Paris, , France

Site Status

Service de dermatologieCHU GUERIN2 rue de la Milétrie

Poitiers, , France

Site Status

BOYE Thierry

Toulon, , France

Site Status

Service de médecine interne-néphrologie Centre Hospitalier Valenciennes

Valenciennes, , France

Site Status

Azienda Ospedaliero Universitaria Policlinico

Bari, , Italy

Site Status

Clinica DermatologicaUnivesité de GênesVialle Benedetto

Genova, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4350

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.